Quantitative Synthesis II: Interactive Quiz Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.
Daniele Santini Università Campus Bio-Medico Roma.
SILEN-C2: sustained virological response (SVR) and safety of BI 201335 combined with peginterferon alfa 2a and ribavirin (PegIFN/RBV) in chronic HCV genotype-1.
Pay for Performance for Medicaid and Safety Net Providers: Innovations and Trends in 2009 March 13, 2009 Dianne Hasselman Center for Health Care Strategies.
1464 Mo Renin inhibitors: the last challenge in the RAAS blockade Alberto Morganti U.O. Medicna Generale e Centro Ipertensione Arteriosa Ospedale San Giuseppe.
High resolution study experiences in Ticino and Switzerland, a selection SEA Malpensa Center, 6 th November 2012 Workshop for a European High Resolution.
The Economic Crisis: The Toll on the Patients and Communities Hospitals Serve April 27, 2009.
The Economic Crisis: Ongoing Monitoring of Impact on Hospitals Results of AHA Rapid Response Survey, August/September 2009 November 11, 2009.
Patient Safety Research Introductory Course Session 3 Albert W Wu, MD, MPH Former Senior Adviser, WHO Professor of Health Policy & Management, Johns Hopkins.
Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated Interferon alpha-2a in treatment naïve chronic.
Tackling over- dispersion in NHS performance indicators Robert Irons (Analyst – Statistician) Dr David Cromwell (Team Leader) 20/10/2004.
New developments in IMPARTS: Integrating Mental and Physical Healthcare: Research Training and Services Website: .